Cardia-cerebrovascular Disease
Conditions
Interventions
experimental group: bisphosphonates
control group:none
Sponsors
First Affiliated Hospital of Bengbu Medical College/Daping Army Special Medical Center
Eligibility
Sex/Gender
All
Age
55 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Aged = 55 years when starting bisphosphonate; 2. Continuous use of bisphosphonate = 5 years or intermittent use of bisphosphonate = 7 years (intermittent days = 2 years); 3. Targeted diseases Laboratory and imaging studies.
Exclusion criteria
Exclusion criteria: 1. Cardiovascular and cerebrovascular diseases have occurred before the use of bisphosphonates, including myocardial infarction, coronary heart disease, ischemic heart disease, cerebral infarction, cerebral hemorrhage, vascular dementia and peripheral vascular disease; 2. Congenital Cardiac, rheumatic heart disease, hypertrophic heart disease, dilated heart disease; 3. People with moyamoya disease, hereditary cerebrovascular disease; 4. Congenital abdominal aorta, renal artery, peripheral artery stenosis or deformity; 5. Patients with parathyroid diseases, such as hypoparathyroidism, hyperparathyroidism, etc.; 6. Use oral calcium supplements or vitamin D other drugs to prevent osteoporosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Carotid intima-media thickness;Aortic calcification;Cerebral stenosis;Cardia-cerebrovascular Disease mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood glucose;Blood lipid examination;blood pressure;liver function;renal function; | — |
Countries
China
Contacts
Public ContactHuadong Zhou
Department of Neurology, Daping Hospital, Army Medical University
Outcome results
None listed